Showing results (191-200 of 331) with videos related to
Sort By:
Pageof 34
The Journal of Clinical Investigation|February 5, 2020
A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapyBalamayoora Theivanthiran, Kathy S Evans, Nicholas C DeVito, et al.Journal for Immunotherapy of Cancer|February 5, 2024
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistanceJamaal L James, Brandie C Taylor, Margaret L Axelrod, et al.The Oncologist|March 13, 2020
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Jennifer L McQuade, Rajat R Rai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2020
Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced MelanomaPaul Johannet, Nicolas Coudray, Douglas M Donnelly, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibGeorgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.Cancer Immunology Research|March 5, 2015
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapiesDouglas B Johnson, Christine M Lovly, Marisa Flavin, et al.Nature Reviews. Cancer|February 20, 2025
Defining a 'cells to society' research framework for appendiceal tumoursAndreana N Holowatyj, Michael J Overman, Konstantinos I Votanopoulos, et al.JCO Precision Oncology|June 29, 2018
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid TumorsAnshuman Panda, Anil Betigeri, Kalyanasundaram Subramanian, et al.JCO Precision Oncology|September 11, 2020
PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaFederica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.Pageof 34